The lawyer advising super-specialty hospital Asian Institute of Medical Sciences (AIMS), which received an investment of US$21 million from UK development finance institution CDC Group, said the deal was interesting as it involved two investors with different visions.
“Representing the company and promoters against two investors with different objectives and visions was interesting and unique,” said Akshat Pande, the managing partner of Alpha Partners, who led a team advising AIMS.
“The existing investor had an interest in retaining the terms of their original agreement and the new investor wanted to renegotiate a number of terms to benefit them. Our outlook was to protect the interest of the promoters and the company and negotiate terms which would not disturb the status quo.”
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.